Advancements in the battle against severe acute respiratory syndrome
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease with a significant morbidity and mortality. The major clinical features include persistent fever, chills/rigor, myalgia, malaise, dry cough, headache and dyspnoea. Respiratory failure is the major complication of SARS and similar to 20% of patients may progress to acute respiratory distress syndrome requiring invasive mechanical ventilatory support. However, the severity is much milder in infected young children. Treatment of SARS was empirical in 2003 due to our limited understanding of this new disease. Protease inhibitors (lopinavir/ritonavir) in combination with ribavirin may play a role as antiviral therapy in the early phase, whereas the role of IFN and systemic steroid in preventing immune-mediated lung injury deserves further investigation. Knowledge of the genomic sequence of the SARS coronavirus has facilitated the development of rapid diagnostic tests. In addition, other antiviral treatment, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed. This paper provides a review of the epidemiology, clinical features and possible treatment strategies of SARS.
著者Hui DSC, Wong GWK
期刊名稱Expert Opinion on Pharmacotherapy
出版年份2004
月份8
日期1
卷號5
期次8
出版社ASHLEY PUBLICATIONS LTD
頁次1687 - 1693
國際標準期刊號1465-6566
電子國際標準期刊號1744-7666
語言英式英語
關鍵詞clinical features; epidemiology; pharmacotherapy; SARS
Web of Science 學科類別Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

上次更新時間 2021-02-05 於 01:31